Genentech has received FDA approval of Lucentis for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA approved Lucentis after a six-month Priority Review and will ship the product immediately. The Phase III trials showed that 95% of patients treated with Lucentis maintained their vision and vision improved by at least three lines (or 15 letters) on the study eye chart in as many as 40% of these patients at one year. Lucentis is an injectable bio-drug designe...